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While isolation of the pulmonary veins is firmly established as effective treatment
for the majority of paroxysmal atrial fibrillation (AF) patients, there is recognition that
patients with persistent AF have substrate for perpetuation of arrhythmia existing
outside of the pulmonary veins. Various computational approaches have been used
to identify targets for effective ablation of persistent AF. This paper aims to discuss
the clinical aspects of computational approaches that aim to identify critical sites for
treatment. Various analyses of electrogram characteristics have been performed with
this aim. Leading techniques for electrogram analysis are Complex Fractionated Atrial
Electrograms (CFAE) and Dominant Frequency (DF). These techniques have been the
subject of clinical trials of which the results are discussed. Evaluation of the activation
patterns of atria in AF has been another avenue of research. Focal Impulse and Rotor
Modulation (FIRM) mapping and forms of Body Surface Mapping aim to characterize
multiple atrial wavelets, macro-reentry and focal sources which have been proposed as
basic mechanisms perpetuating AF. Both invasive and non-invasive activation mapping
techniques are reviewed. The presence of atrial fibrosis causes non-uniform anisotropic
impulse propagation. Therefore, identification of fibrosis by imaging techniques is an
avenue of potential research. The leading contender for imaging-based techniques is
Cardiac Magnetic Resonance (CMR). As this technology advances, improvements in
resolution and scar identification have positioned CMR as the mode of choice for analysis
of atrial structure. AF has been demonstrated to be associated with obesity, inactivity and
diseases of modern life. An opportunity exists for detailed computational analysis of the
impact of risk factor modification on atrial substrate. This ranges from microstructural
investigation through to examination at a population level via registries and public health
interventions. Computational analysis of atrial substrate has moved from basic science
toward clinical application. Future directions and potential limitations of such analyses
are examined in this review.
Keywords: atrial fibrillation, ablation techniques, lifestyle interventions, mapping & localization, fibrosis, imaging,
three-dimensional, imaging
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INTRODUCTION
While isolation of the pulmonary veins (PVI) is firmly established
as effective treatment for the majority of paroxysmal atrial
fibrillation (AF) patients,(Calkins et al., 2017) there is recognition
that patients with persistent AF have substrate for perpetuation
of arrhythmia existing outside of the pulmonary veins.
Computational approaches have been attempted in the search
to identify targets for effective ablation of persistent AF. We
aim to discuss the clinical aspects of computational approaches
that seek to identify critical sites for ablation in the treatment of
persistent AF. We explore the initial approach of electrogram-
based analyses through to more topical panoramic mapping of
AF substrate. We look at the role of imaging to identify atrial scar
as a potential AF ablation target and the recent recognition that
lifestyle management is very important in reducing AF burden.
Lastly, we explore potential future directions to advance AF care
via computational approaches.
Electrogram-Based Approach
Complex Fractionated Atrial Electrograms
Electrophysiologists skilled in ablation of arrhythmias have
sought to look for characteristics of electrograms that might
identify critical sites for ablation. The elimination of complex
fractionated atrial electrograms (CFAE) has been shown in
some studies to be an effective strategy of catheter ablation
(Nademanee et al., 2004, 2008) Fractionated or prolonged
electrograms have been demonstrated to identify areas acting as
pivot points, slowed conduction, anisotropy, localized circuits or
rotors, all of which are capable of sustaining re-entry (Spach and
Dolber, 1986; Konings et al., 1994; Haïssaguerre et al., 2006).
Accurately identifying such electrograms may allow targeted
ablation to halt wavelet re-entry and prevent the perpetuation of
AF.
Initially, CFAE were defined as fractionated electrograms
composed of ≥2 deflections, perturbation of the baseline with
continuous deflection of a prolonged activation complex, or
atrial electrograms with a cycle length ≤120ms (Nademanee
et al., 2004) However, as this method of ablation became more
widespread, a more consistent definition of ablation targets was
desired, particularly if one wanted to perform a multi-center
trial where standardization across hospitals was paramount.
Hence, computer algorithms were designed to provide consistent
definitions of CFAE, independent of the operator’s discretion.
These included the CFAE software module (CARTO, Biosense
Webster, CA, USA) and the CFE-mean tool (NavX, Abbott, CA,
USA).
The CFE-mean tool was used to test the usefulness of CFAE
ablation in addition to PVI and linear lesions in the BOCA study
of 130 persistent AF patients (Wong K. C. et al., 2015) This trial
found no additional benefit in the patients randomized to CFAE
ablation, despite longer procedure and ablation times. There was
an excess of organized atrial arrhythmia, in particular gap-related
macro-re-entrant flutter, in the patients randomized to CFAE
ablation. In themulti-center STAR-AF II trial (Verma et al., 2015)
the use of a computerized algorithm to detect standardized CFAE
electrograms was employed. This trial showed no additional
benefit of CFAE ablation as guided by the CFE-mean tool in
addition to PVI alone, in patients with persistent AF. Indeed,
some have used this trial to suggest that CFAE-targeted ablation
is detrimental to long-term outcome (Conti and Verma, 2016)
The CHASE-AF trial produced similar conclusions, where no
benefit from the addition of a CFAE-based ablation strategy
over non-CFAE ablation was seen (Vogler et al., 2015) A recent
meta-analysis confirmed that the addition of extra-pulmonary
substrate ablation such as that of CFAE in persistent AF patients,
was associated with declining efficacy as compared to PVI
ablation alone (Clarnette et al., 2017).
However, strong proponents of CFAE-based ablation argue
that computer-derived 3D maps of fractionation are inaccurate
and lead to different areas being targeted, compared to the
areas targeted when visual recognition of CFAEs are made by
experienced operators (Oketani et al., 2016) For example, the
semi-automated CFAE algorithms from the NavX and CARTO
systems were found to correlate poorly with each other or
AF complexity measures that may explain the variable results
of CFAE-based ablation. Furthermore, the dynamic nature of
CFAE with poor temporal stability may be another challenge
for CFAE-based ablation based on point-by-point mapping (Lau
et al., 2012) Novel indices such as unipolar fractionation index
or spatiotemporal stability index of CFAE have been shown to
demonstrate superior physiological relevance to AF dynamics
(Lau et al., 2015; Thanigaimani et al., 2017a) Therefore, there
perhaps remains a role for novel computerized algorithms used
in combination with higher density mapping catheter that could
better direct electrophysiologists to critical AF-sustaining sites.
Dominant Frequency
Dominant frequency (DF) analysis aims to distill the local
activation frequency from highly complex electrograms. This
utilizes computer algorithms (usually fast fourier transform) to
assign a fundamental frequency of electrical activation. The DF
can then be displayed on a 3D map to guide the ablator to
sites of high DF thought to be driving the AF (focal source
or rotor). The aim of such analysis is to detect sites of high
frequency that have been hypothesized to “drive” the fibrillation
process (Jalife et al., 2002) These sites have been shown by
retrospective analysis to identify effective ablation areas (Sanders
et al., 2005) In an elegant animal study by Kalifa et al, areas
of fractionation were demonstrated at the periphery of areas of
high dominant frequency (Kalifa et al., 2006) The proximity of
high DF and CFAE sites has also been demonstrated in high-
density mapping of human AF (Stiles et al., 2008) Of note, most
studies examining DF guided ablation have used off-line analysis,
although real-time analysis has also been reported albeit without
incremental outcome (Atienza et al., 2014) In a systematic review
of DF-based approaches, Gadenz et al concluded that DF-based
approaches are a useful marker of ablation outcome; however,
direct intervention targeting DF sites appears premature with
mixed results and too few studies (Gadenz et al., 2017) A more
recent study using a novel frequency analysis algorithm and
longer duration of AF electrograms in search for temporally
stable AF drivers has shown some promise (Kimata et al., 2018)
Ongoing work will help refine our armamentarium toward future
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targeting of high DF sites to improve outcomes (Sanders et al.,
2018).
Shannon Entropy
The detection of points of high Shannon Entropy has been
postulated as a way of mapping drivers of AF (Ganesan et al.,
2014) In particular, ablation at the point of “phase singularity” has
been shown to lead to termination of atrial fibrillation (Narayan
et al., 2012) Recordings at the center of a rotor should have
less directional information in the local bipolar electrogram than
recordings away from the center. Maximum Shannon Entropy
has been shown to be co-located at the center of rotational activity
from experimental models of atrial fibrillation (Ganesan et al.,
2014) Furthermore, Shannon Entropy of bipolar electrograms
has been shown to be consistent across models and differences
in electrode spacing, signal filtering and rotor meander (Ganesan
et al., 2014) Studies examining ablation outcome based on
Shannon Entropy guided ablation are ongoing.
With the number of promising computational approaches
seeking to gather additional information from electrograms,
some have sought to show which technique is best, or whether
a hybrid approach combining multiple approaches is superior.
Hwang et al looked at phase singularity, DF, Shannon entropy
and CFAE cycle length with subsequent ablation in 2D and
3D simulation models and found that DF-based ablation was
superior for AF termination (Hwang et al., 2016) However, no
human AF studies have been able to replicate such data and
it remains an area where computational based approaches to
electrogram analysis may yet yield insights into effective ablation
targets for human AF.
Panoramic Mapping of AF Mechanisms
Over the last decade, the field has progressed from electrogram-
based AF mapping to focus on activation and phase mapping
to detect AF drivers in the form of rotational (“rotors”) and
ectopic focal (“foci”) activations. First descriptions of rotational
activations were from studies that undertook sequential mapping
with multi-polar spiral catheter (Atienza et al., 2011; Ghoraani
et al., 2013) The Focal Impulse and Rotor Modulation (FIRM)
guided technique was the first panoramic mapping study
that showed high success rates with ablating AF drivers
(Narayan et al., 2012). Other panoramic mapping techniques
included body surface potentials mapping with inverse-solution
electrocardiographic imaging (ECGI) (Haissaguerre et al., 2014)
mapping of wavefront propagation using intracardiac multipolar
catheter (CARTOFINDER) (Honarbakhsh et al., 2018) and non-
contact mapping using a multielectrode array catheter (ENSITE)
(Yamabe et al., 2016; Lee et al., 2017). Table 1 summarizes
the different panoramic mapping techniques utilized toward
detection of AF rotors and foci.
Focal Impulse and Rotor Modulation (FIRM)
The FIRM technique is facilitated by a 64-pole basket type
catheter with phase-based signal processing to detect AF rotors or
foci. The algorithm has remained proprietary, with utilization of
electrogram data such as local refractoriness and restitution. The
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patient that conserved for tens of minutes. In this study, FIRM-
guided ablation was superior to conventional ablation with 86 vs.
20% acute termination or slowing of AF, and 82.4% vs. 44.9%
freedom from AF after a median of 9 months (Narayan et al.,
2012). Further, follow-up of these patients to 3 years showed
durable success with 77.8% of the FIRM-guided ablation group
remained free of AF vs. 38.5% in the conventional group after a
mean of 1.2 procedures (Narayan et al., 2014).
However, subsequent studies have shown a wide variability
in the reported outcomes from FIRM-guided ablation. A recent
meta-analysis (10 studies, n = 527 patients) showed a pooled
estimate of single-procedure freedom from AF of only 59.2%
in non-paroxysmal AF at a mean follow-up of 12.9 months,
with a high level of heterogeneity seen among studies (I2
= 88.3%) (Parameswaran et al., 2018). The variability in
outcomes could be due to the limitations in the use of the
basket type catheter including suboptimal electrode contact or
chamber coverage where potential absence of septal coverage
and <25% of overall left atrial surface area coverage have
been reported (Pathik et al., 2018). The assumption that the
electrodes of the basket catheter are evenly spread over a
2-D grid as opposed to the actual variable spread in a 3-
D orientation may contribute to potential errors in phase-
based signal analysis of focal sources (Pathik et al., 2018).
Further, it is unclear whether electrode density or spacing
of the basket catheter may also affect detection of focal
sources (Walters et al., 2016; Kuklik et al., 2017). There are
also concerns regarding the validity of the FIRM technique
whereby comparative assessments failed to identify the same
temporally stable rotors as identified by FIRM, with absence of
distinctive electrophysiological characteristics of rotors in terms
of dominant frequency and Shannon Entropy (Benharash et al.,
2015; Halbfass et al., 2017). Several ongoing randomized trials
will provide further guidance on the utility of FIRM guided
ablation.
Electrocardiographic Imaging (ECGI)
The ECGI is a non-invasive body surface potentials mapping
technique using a 252-electrode vest with inverse solution
to derive virtual potentials on the epicardial atrial surface
localized with thoracic computed tomography. Additional signal
processing of wavelet transform and phase mapping are then
applied to detect AF sources. Initial report of ECGI mapping in
26 AF patients found mainly multiple wavelets and ectopic foci
with rare rotor activities seen in 15% only (Cuculich et al., 2010).
More recent ECGI mapping study of 103 persistent AF patients
showed a median of 4 driver regions per patient that consisted
of non-sustained repetitive rotors (median 2.6 rotations) with
substantial meandering as well as ectopic focal sources that
fired a mean of 6 times. In this study, the rotors accounted for
80.5% of all AF drivers with the remaining 19.5% consisted of
ectopic foci. Importantly, ablation of these drivers resulted in AF
termination in 80% and in these cohort of patients, AF freedom
was 85% at 1 year follow-up (Haissaguerre et al., 2014). In
addition, the ECGI data from the same group also demonstrated
increased complexity of these AF drivers with prolonged AF
duration. Specifically, longer duration of AF was associated with
increased numbers of rotors and ectopic foci, increased number
of regions with these AF drivers and extrapulmonary drivers,
such as from the infero-posterior left atrium and the anterior left
atrium/septal region. Ablation targeting these driver sites resulted
in AF termination in 70% of the persistent AF patients (Lim
et al., 2017). However, there are several shortcomings with this
mapping modality such as the inability to detect activations in
the interatrial septum or the ridge between the pulmonary vein
and left atrial appendage, reduced ability to detect low amplitude
signals as well as the inability to distinguish between micro-entry
and epicardial breakthrough activations (Cuculich et al., 2010;
Haissaguerre et al., 2014).
CARTOFINDER
This is a mapping approach that utilizes existing CARTO 3-
D electroanatomical mapping system (Biosense Webster, CA,
USA) with a module called CARTOFINDER which is still in the
development phase. The first report using this system included
13 persistent AF patients where mapping was performed with the
PentaRay catheter in both the right and left atrium. In brief, it
utilizes unipolar electrograms for phase analysis using Hilbert
Transform to detect rotors as well as bipolar electrograms for
dominant frequency analysis to gauge ablation efficacy. A mean
of 1.8 rotor domains (mean 9.2 rotations) was seen in each
patient while ablation of these sites resulted in reduction in
dominant frequency, acute termination to sinus rhythm in 2 out
of 13 patients (15%) and 1-year freedom from AF rate of 70%
(Calvo et al., 2017). In another CARTOFINDER study, activation
mapping was performed with the basket catheter in 20 persistent
patients without using phase based analysis. Here, the AF drivers
were transient (mostly ≤4 cycles) but repetitive in separate maps
while ablation of these resulted in significant effect of termination
or slowing of cycle length in 85% (Honarbakhsh et al., 2018).
More outcome data are awaited as this system matures in its
development.
Ensite Non-contact Multi-Electrode Array
Several groups have used the Ensite multi-electrode array
catheter (St Jude Medical, MN, USA) for panoramic non-contact
AF mapping (Yamabe et al., 2016; Lee et al., 2017). This is a
commercially available system that affords recording of unipolar
virtual electrograms that can be superimposed onto the 3-
D endocardial geometry to display wavefront propagation as
animated isopotential color map. Using this technique, transient
AF rotors were seen in 1 out of 15 persistent AF and 10 out of
60 paroxysmal AF patients that lasted for a mean of 6.1 s in one
study (Yamabe et al., 2016). In another study, the Ensite non-
contact mapping system failed to identify any focal sources in
15 persistent AF patients (Lee et al., 2017). There are no data
available regarding ablation of AF rotors or foci detected with this
system.
Electrophysiological Characterization of AF Drivers
The various panoramic mapping methods described above
represent intensive research in the field in search of AF driver
sites. Many studies have provided increasing insights regarding
the electrophysiological characteristics of these drivers despite
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apparent differences seen in the dynamics of AF drivers.
For example, all panoramic mapping modalities have found
AF driver sites to be non-sustained except for the FIRM
technique where AF drivers lasted for tens of minutes. The
transient nature of AF drivers is in keeping with direct contact
mapping studies in long-lasting persistent AF patients (Lee
et al., 2014; Walters et al., 2015). Nevertheless, there appears
to be agreement on the meandering nature of these drivers
that appear repetitively at similar locations in the same patient,
namely near the pulmonary vein ostia, left atrial appendages,
septum and coronary sinus-inferior left atrium. The anatomical
clustering of AF drivers is in keeping with the known importance
of structures annexed to the left atrium and the presence of
complex muscle fiber orientations at such sites (Haïssaguerre
et al., 2005).
Further analysis of the ECGI detected driver sites have
unveiled increased electrogram fractionation and their
proximity to areas with increased fibrosis as assessed by
late gadolinium-enhanced magnetic resonance imaging (LGE-
MRI) (Haissaguerre et al., 2016). However, others have not been
able to show the same relationship between AF drivers and
LGE-MRI detected fibrotic regions (Chrispin et al., 2016; Sohns
et al., 2017). Nevertheless, novel 3-D computational framework
provides evidence that AF drivers may be identifiable by a
distinct structural “fingerprints” that consist of intermediate
wall thickness, intermediate fibrosis and twisted myofiber
orientation (Zhao et al., 2017). Taken together, further work is
needed to refine our understanding of AF drivers and resolve the
differences seen in the their dynamics to guide ablative therapy.
The non-disclosures of proprietary algorithms in the detection
of AF drivers may be a major obstacle toward rapid translation
into clinical practice. Advancement in catheter technology and
design to afford better chamber coverage with higher electrode
density will also aid in the search of AF drivers amidst the
irregularly irregular atrial activations of this highly complex
arrhythmia.
Targeting Atrial Fibrosis
Atrial fibrosis is known to result in non-uniform anisotropic
impulse propagation and increased conduction heterogeneity
that may perpetuate AF by favoring re-entry and anchoring of
AF drivers (Maesen et al., 2013; Haissaguerre et al., 2016). These
structural and conduction changes have been consistently seen
in different atrial substrates such as hypertension, obesity, heart
failure, valvular heart disease, diabetes, aging and obstructive
sleep apnea (Sanders et al., 2003; Kistler et al., 2004; Kato et al.,
2006; John et al., 2008; Lau et al., 2010, 2011a, 2013b; Medi
et al., 2011; Dimitri et al., 2012; Abed et al., 2013a; Iwasaki
et al., 2014). In addition, AF itself can result in increased
atrial fibrosis in the absence of any risk factors (Stiles et al.,
2009; Verheule et al., 2013; Corradi et al., 2014). The signaling
mechanisms involved in atrial fibrosis are highly complex and
remain incompletely understood (Thanigaimani et al., 2017b).
Several agents have been studied in experimental models and
have been found to be effective in attenuating or preventing
atrial fibrosis: renin-angiotensin-aldosterone inhibitors,(Li et al.,
2001; Milliez et al., 2005) n-3 polyunsaturated fatty acids,
(Lau et al., 2011b) HMG-CoA reductase inhibitors,(Shiroshita-
Takeshita et al., 2007) and various anti-fibrotics such as tranilast,
pirfenidone and relaxin (Lee et al., 2006; Nakatani et al., 2013;
Parikh et al., 2013; Henry et al., 2016). Unfortunately, human
studies of these agents remain lacking for translation into clinical
practice.
Traditional assessment of atrial electrical changes has been
facilitated by 3-D electroanatomical maps to evaluate atrial
voltage, conduction velocity and electrogram fractionation
(Figure 1; Lau et al., 2017). Advances in cardiac imaging have
facilitated non-invasive quantification of atrial fibrosis by means
of LGE-MRI (Oakes et al., 2009). Atrial fibrosis assessed with
LGE-MRI has been shown to associate well with regions of low
bipolar left atrial voltage as determined by 3-D electroanatomical
systems (Malcolme-Lawes et al., 2013; Zghaib et al., 2018). In
addition, it has been demonstrated that the degree of atrial
fibrosis detected by LGE-MRI increased with AF persistence
and the presence of more AF risk factors (Daccarett et al.,
2011; McGann et al., 2014). Importantly, atrial fibrosis defined
by LGE-MRI has been shown to be independently associated
with AF recurrence in patients undergoing catheter ablation
in the delayed-enhancement MRI determinant of successful
radiofrequency catheter ablation of AF (DECAAF) study
(Marrouche et al., 2014). Further analysis of 177 of the DECAAF
patients who underwent repeat LGE-MRI scanning 90 days post-
ablation showed that the greater overlap of ablation induced
scarring over pre-ablation fibrosis, the better the arrhythmia
free survival (Akoum et al., 2015). Ongoing prospective multi-
center randomized controlled trial (DECAAF-II) will examine
the efficacy of targeting LGE-MRI detected atrial fibrosis in
persistent AF patients.
However, several technical challenges with LGE-MRI
detection of atrial fibrosis have been acknowledged. These
include issues such as spatial resolution given the thin atrial
walls, motion artifact especially when the patient is not in sinus
rhythm, the lack of standardized image acquisition protocols
and the all-important quantitation of the amount of LGE that
can be subjective and labor intensive even if signal intensity
thresholding was employed over visual assessment (Appelbaum
and Manning, 2014; Pontecorboli et al., 2017). It is also noted
that there remains a paucity of good quality data whereby
LGE-MRI detected atrial fibrosis or post-ablation scars have been
histologically validated (Harrison et al., 2014; McGann et al.,
2014). Therefore, it is of no surprise that the reproducibility
of LGE-MRI analysis has been questioned and the diagnostic
accuracy of this modality to detect ablation lesions has been
shown to be suboptimal (Hunter et al., 2013; Pontecorboli
et al., 2017). Alternatively, post-contrast cardiac MRI atrial
T1 relaxation time mapping has been shown to be a reliable
index of atrial fibrosis that correlated with atrial voltage and
ablation outcome (Ling et al., 2014). However, the inability
of T1 mapping technique to provide spatial distribution of
atrial fibrosis will hamper its ultimate usage to guide ablative
therapy. Hopefully, the LGE-MRI technique will mature toward
standardization of image acquisition, automation of image
analysis, improved image resolution and validation in the not too
distant future.
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FIGURE 1 | Electroanatomical maps and electrophysiological changes in various AF substrates. 3-D electroanatomical maps from various AF substrates are shown
with bipolar voltage scaled from <0.05mV (red) to >5mV (purple). Points with fractionated or double potentials or scar are annotated with red, blue, and gray dots
respectively. Figure used by permission from Lau et al. (2017) © American Heart Association.
Targeting the AF Risk Factors
Despite the advances in catheter ablation technology and
strategies over the last two decades, the field has not witnessed
a significant improvement in ablation success especially in those
with persistent AF (Brooks et al., 2010; Clarnette et al., 2017).
It is well recognized that there is a long-term attrition in
sinus rhythm maintenance following initially successful catheter
ablation (Ganesan et al., 2013). In addition, progressive atrial
substrate changes have been documented in individuals despite
a successful AF ablation procedure (Teh et al., 2012). A myriad
of AF risk factors have been identified to contribute to the
progressive AF substrate and recurrences post catheter ablation
procedures. These include: aging, left atrial enlargement, heart
failure, hypertension, aortic stiffness, valvular heart disease,
obesity, pericardial fat, diabetes mellitus, dyslipidemia and
obstructive sleep apnea (de Vos et al., 2010; Ng et al., 2011; Wong
et al., 2011; Mohanty et al., 2012; Lau et al., 2013a; Jacobs et al.,
2015; Proietti et al., 2015; Wong C. X. et al., 2015; Linz et al.,
2018). Therefore, effortsmust be placed to target these risk factors
to maximize rhythm control outcome in patients with AF.
There is prospective randomized evidence showing that a
targeted weight loss intervention reduced atrial dilatation, left
ventricular hypertrophy, and AF symptom burden and severity
in highly symptomatic overweight and obese patients with AF
(Abed et al., 2013b). Tight control of systolic blood pressure
to under 130 mmHg has been shown to reduce incident and
recurrent AF in hypertensive subjects although a more recent
study reported neutral results (Thomas et al., 2008; Okin
et al., 2015; Parkash et al., 2017). Continuous positive airway
pressure therapy has been shown to improve sinus rhythm
maintenance in patients with obstructive sleep apnea undergoing
electrical cardioversion and catheter ablation (Linz et al., 2018).
A structured, physician-driven, and goal-directed weight and
risk factor management strategy has been applied in overweight
and obese patients with AF to good success, as seen in the
ARREST-AF (Aggressive Risk Factor Reduction Study for Atrial
Fibrillation and Implications for the Outcome of Ablation)
and LEGACY (Long-Term Effect of Goal Directed Weight
Management on an Atrial Fibrillation Cohort) studies (Figure 2).
In brief, this program involved weight management by dietary
modification, tailored moderate-intensity exercise to improve
cardiorespiratory fitness, targeted strict systolic blood pressure
control to <130mmHg, lipid and glycemic management aiming
for low-density lipoprotein <2.6 mmol/L and hemoglobin A1c
<6.5%, active screening and treatment of obstructive sleep apnea
with continuous positive airways pressure therapy, smoking
cessation and alcohol reduction to <3 standard drinks per week.
In addition, gain in cardiorespiratory fitness was found to confer
greater freedom from AF independent of weight loss.
Additional evidence on the benefits of exercise in AF can
be seen from the study by Malmo and co-workers with aerobic
interval training for 12 weeks (Malmo et al., 2016). Similarly,
weight and exercise intervention has been shown to confer
equivalent benefits to re-do catheter ablation in a study in
patients with post-ablation AF recurrences (Mohanty et al.,
2014). More recently, in persistent AF patients with heart failure,
a multi-center prospective randomized study has demonstrated
that additional intervention targeting the underlying conditions
with cardiac rehabilitation including physical activity, dietary
restrictions, and counseling, mineralocorticoid receptor
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FIGURE 2 | Beneficial effects of various lifestyle modifications. The benefits of lifestyle and risk factor modifications on AF-free survival are evident from these
Kaplan-Meier survival graphs: (A) Greater freedom from AF was seen with greater degree of weight loss (WL) in the LEGACY study. (B) Risk factor management (RFM)
confers greater AF-free survival following catheter ablation procedure vs. usual care in the ARREST-AF Cohort Study. (C) Gain in cardiorespiratory fitness (MET,
metabolic equivalent) confers independent and incremental AF free survival to WL in the CARDIO-FIT study.
antagonist, HMG-CoA reductase inhibitor and angiotensin
converting enzyme inhibitors and/or receptor blockers resulted
in improved sinus rhythm maintenance at 1 year (Rienstra et al.,
2018). Taken together, the mounting evidence regarding the
benefits of these lifestyle and risk factor management approaches
and their cost-effectiveness warrants their incorporation as
routine “4th pillar” of AF care to maximize outcomes (Lau et al.,
2017; Pathak et al., 2017). This can be achieved by combining the
risk factor management component with a wider integrated AF
clinic to optimize care delivery (Hendriks et al., 2012).
Future Directions
Novel computational approaches that help identify the
arrhythmogenic substrate of AF have the potential to advance
the field of AF ablation. The progression of electrogram
analysis through to dynamic substrate mapping has been
increasingly reliant on the computational approach. Recognition
that atrial microstructure is critical to the maintenance of
persistent AF should stimulate future analyses to benefit
from the increasing resolution of imaging studies, particularly
MRI. However, with increasing resolution comes reliance
on computing power and bespoke algorithms to take best
advantage of it.
As we move into the world of meta-data and wearable
technology, a computational approach to analysis of the data
may afford increased detection of AF as well as giving additional
insights to physical activity and its impact on AF incidence.
Personalized exercise and weight reduction programmes for
patients with AF delivered via smartphone technology will
integrate with aggressive risk factor management clinics.
Computational analysis of effectiveness and the consequent
outcomes for AF will no doubt be an important future
application.
CONCLUSION
Recent developments in computational approaches to ablation
of atrial fibrillation have focused on identifying drivers for the
perpetuation of this arrhythmia. The future of detecting critical
sites for ablation depends largely on a computational approach.
However, large data analyses may also play a role in lifestyle
adjustment which is now recognized to be an important part of a
comprehensive patient management programme for AF.
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